ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
October 26, 2021OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 in Australia. -
OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management
June 11, 2021OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that it is expanding its Scientific Advisory Board ("SAB") for SCN9A antisense pain killer OLP-1002 to include ...
Pharma Sources Insight January 2025
